IP Library Granted Patent US 9,632,093
Granted Patent B2
US 9,632,093 · App. 15/197,105 · Granted Apr 25, 2017

Detecting neoplasm

Inventors: William R. Taylor (Lake City, MN); Jonathan J. Harrington (Madison, WI); Patrick S. Quint (Kasson, MN); Hongzhi Zou (Middleton, WI); Harold S. Bergen, III (Spring Valley, MN); David I. Smith (Rochester, MN); David A. Ahlquist (Rochester, MN)
Assignee: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
G01N33/57438C12Q1/37C12Q1/40C12Q1/6886C12Y302/01001C12Y304/2107G01N33/57407G01N33/57419C12Q2600/154C12Q2600/156G01N2333/928G01N2333/966G01N2560/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,632,093
App. No.
15/197,105
Granted
Apr 25, 2017
Kind
B2
Abstract

This document relates to methods and materials for detecting premalignant and malignant neoplasms. For example, methods and materials for determining whether or not a stool sample from a mammal contains nucleic acid markers or polypeptide markers of a neoplasm are provided.

Claims (9)

1. A method for characterizing a biological sample comprising:

(a) obtaining a biological sample from a human individual;

(b) measuring a K-ras mutation score within the obtained biological sample through exposing a portion of the biological sample to one or more K-ras specific primers and determining the K-ras mutation score by performing a digital melt curve analysis or quantitative allele-specific PCR, wherein the K-ras specific primers comprise a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 2, 3, 4, 5, 6, 7 and 8;

(c) measuring a methylation level of a CpG site for BMP3 in a portion of the obtained biological sample through

treating genomic DNA in the biological sample with bisulfite;

amplifying the bisulfite-treated genomic DNA using primers specific for BMP3, and determining the methylation level of the CpG site by methylation-specific PCR, quantitative methylation-specific PCR, methylation-sensitive DNA restriction enzyme analysis, quantitative bisulfite pyrosequencing, or bisulfite genomic sequencing PCR;

(d) comparing the K-ras mutation score and the BMP3 methylation level to a corresponding set of control samples without colorectal cancer; and

(e) determining that the individual has colorectal cancer when 1) the measured K-ras mutation score is higher than in the control sample, and 2) the measured BMP3 methylation level is higher than in the control sample.

2. The method of claim 1 , wherein the biological sample is a stool sample, a tissue sample, a blood sample, or a urine sample.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 15, 2016
From: TAYLOR, WILLIAM R.; HARRINGTON, JONATHAN J.; QUINT, PATRICK S.; ZOU, HONGZHI; BERGEN, HAROLD R., III; SMITH, DAVID I.; AHLQUIST, DAVID A.
To: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
Reel/Frame 040990/0177 →
Continuity (5)
Continuation 14827013 · Aug 14, 2015
Continuation 14168552 · Jan 30, 2014
Continuation 12866558
Provisional Application 61029221 · Feb 15, 2008
Related Publication 20160305946A1 · Oct 20, 2016